International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation
Generics Players Could Benefit From Greater Control Over Their Prices In 2023
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
You may also be interested in...
Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.
The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.
Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.